TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19140204

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg/d rhIL-18
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg/d rhIL-18
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg/d rhIL-18
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All groups (0.01, 0.1, 1.0 mg/kg/d rhIL-18)
Number of subjects: 64
Study: 17724555

Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation programme in a warm climate
Number of subjects: 60
Study: 15121266

Group type: EXPERIMENTAL
Intervention: Low-dose midazolam with propofol (0.03 mg/kg midazolam + 0.7 mg/kg bolus propofol + 2 mg/kg/h propofol infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol alone (0.7 mg/kg bolus propofol + 2 mg/kg/h propofol infusion)
Number of subjects: 30
Study: 12427437

Group type: EXPERIMENTAL
Intervention: 1 mg of intravenous glucagon
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intravenous glucagon (Control)
Number of subjects: 40
Study: 10075343

Group type: EXPERIMENTAL
Intervention: 15 g oligofructose/d
Number of subjects: 12

Group type: COMPARATOR
Intervention: sucrose (control treatment)
Number of subjects: 12
Study: 7559195

Group type: EXPERIMENTAL
Intervention: Cefotiam hexetil (CTM) 200 mg bd for 5 days
Number of subjects: 250

Group type: COMPARATOR
Intervention: Penicillin V (PEV) 1 megaunit (600 mg) tds for 10 days
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cefotiam hexetil (CTM)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Penicillin V (PEV)
Number of subjects: 250
Study: 1958992

Group type: EXPERIMENTAL
Intervention: Choledochoscopy
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (no choledochoscopy)
Number of subjects: 157
Study: 7003391

Group type: EXPERIMENTAL
Intervention: Colestipol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colestipol plus clofibrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colestipol plus niacin
Number of subjects: 0
Study: 6381000

Group type: EXPERIMENTAL
Intervention: Preparation-H
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30097422

Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy (guided ICBT)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 258
Study: 27385750

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Number of subjects: 1456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Hand-held dynamometry (HHD)
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: ALSFRS-R
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Vital capacity
Number of subjects: 1456
Study: 24962637

Group type: EXPERIMENTAL
Intervention: Individuals with LOC eating
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individuals without LOC eating
Number of subjects: 80
Study: 20456255

Group type: EXPERIMENTAL
Intervention: Riboflavin UV A corneal collagen cross-linking (CXL)
Number of subjects: 44
Study: 21098406

Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST), 4 weeks, 5 days per week, 20 minutes per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham control group
Number of subjects: 60
Study: 18482817

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/d)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Ticlopidine (200 mg/d)
Number of subjects: 127
Study: 15966376

Group type: EXPERIMENTAL
Intervention: landiolol 125 microg x kg(‐1) x min(‐1) for one minute followed by 40 microg x kg(‐1) x min(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: landiolol
Number of subjects: 40
Study: 12927226

Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10975959

Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8762419

Group type: EXPERIMENTAL
Intervention: Yiqi Mianyi Granule (YQMYG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Zhenqi Fuzheng Granule (ZQFZG)
Number of subjects: 72
Study: 1987848

Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 782
Study: 6340015

Group type: EXPERIMENTAL
Intervention: 0.5 percent bupivacaine 1/200,000 epinephrine
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2 percent lidocaine 1/100,000 epinephrine
Number of subjects: 32
Study: 31825895

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1329
Study: 29709070

Group type: EXPERIMENTAL
Intervention: Active Bio‐Electro‐Magnetic‐Energy‐Regulation (BEMER) device
Number of subjects: 108

Group type: COMPARATOR
Intervention: Inactive device (sham treatment)
Number of subjects: 108
Study: 27921992

Group type: EXPERIMENTAL
Intervention: Haemorrhoidal artery ligation (HAL)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Rubber band ligation (RBL)
Number of subjects: 370
Study: 25102685

Group type: EXPERIMENTAL
Intervention: Chinese herbs for clearing heat and promoting diuresis (n = 126)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Western Medicine (n = 60)
Number of subjects: 186
Study: 22906218

Group type: EXPERIMENTAL
Intervention: Discussion in a Computer Supported Collaborative Learning (CSCL) environment
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Revised papers
Number of subjects: 47

Group type: COMPARATOR
Intervention: Unrevised papers
Number of subjects: 47
Study: 20708062

Group type: EXPERIMENTAL
Intervention: Mandibular 2‐implant overdentures (IODs)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Conventional dentures (CDs)
Number of subjects: 214
Study: 17420340

Group type: EXPERIMENTAL
Intervention: Simultaneous Biventricular (BiV) pacing
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Sequential Biventricular (BiV) pacing
Number of subjects: 306

Group type: COMPARATOR
Intervention: Left Ventricular (LV) pacing
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: All groups (Simultaneous BiV, Sequential BiV, LV pacing)
Number of subjects: 306
Study: 15746297

Group type: EXPERIMENTAL
Intervention: Intranasal phenoxybenzamine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11978254

Group type: EXPERIMENTAL
Intervention: Delayed prescription
Number of subjects: 129

Group type: COMPARATOR
Intervention: Immediate prescription
Number of subjects: 129
Study: 9639218

Group type: EXPERIMENTAL
Intervention: 30 mg intravenous dexamethasone over 36 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: No steroid medication (control group)
Number of subjects: 30
Study: 8033493

Group type: EXPERIMENTAL
Intervention: Intravenous torsemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral torsemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Torsemide (both intravenous and oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 0
Study: 2466880

Group type: COMPARATOR
Intervention: Prednisone (20 mg every 8 hours for 48 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nasal antigen challenge
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonatopic subjects
Number of subjects: 20
Study: 1234498

Group type: EXPERIMENTAL
Intervention: Oral (‐‐)‐tryptophan (5 g)
Number of subjects: 0
Study: 31157566

Group type: EXPERIMENTAL
Intervention: Automated bolus calculator (ABC) (Accu‐Check Aviva Expert)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Manual insulin calculations (control)
Number of subjects: 65
Study: 27531024

Group type: EXPERIMENTAL
Intervention: 12-week telephone-delivered exercise intervention from peer volunteers
Number of subjects: 76

Group type: COMPARATOR
Intervention: Contact control condition
Number of subjects: 76
Study: 25884936

Group type: EXPERIMENTAL
Intervention: Assisted partner notification services at intervention sites
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Passive partner referral at control sites
Number of subjects: 1080
Study: 23611105

Group type: EXPERIMENTAL
Intervention: Memory and Aging Program (n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control (n = 21)
Number of subjects: 42
Study: 21292168

Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg once daily
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg twice daily
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Alvimopan (both doses)
Number of subjects: 485
Study: 19404071

Group type: EXPERIMENTAL
Intervention: Ultracision
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ligasure
Number of subjects: 140

Group type: COMPARATOR
Intervention: Both
Number of subjects: 140
Study: 17942736

Group type: EXPERIMENTAL
Intervention: Progesterone (allopregnanolone)
Number of subjects: 0
Study: 14736307

Group type: EXPERIMENTAL
Intervention: Presence of implausible alternatives (duds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonnumeric likelihood measures and betting measures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Numeric likelihood measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 0
Study: 11314848

Group type: EXPERIMENTAL
Intervention: Personalised feedback
Number of subjects: 801

Group type: COMPARATOR
Intervention: Control group (no personalised feedback)
Number of subjects: 801
Study: 9427984

Group type: EXPERIMENTAL
Intervention: 0.2 mg/ml mitomycin-C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.4 mg/ml mitomycin-C
Number of subjects: 30
Study: 8490542

Group type: EXPERIMENTAL
Intervention: Dietary intervention (caloric restriction adapted to personal needs and behavior)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study: 3098341

Group type: EXPERIMENTAL
Intervention: 0.025 mg transdermal oestradiol daily
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.05 mg transdermal oestradiol daily
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.1 mg transdermal oestradiol daily
Number of subjects: 3
Study: 30526778

Group type: EXPERIMENTAL
Intervention: Menopausal group
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Post-menopausal group
Number of subjects: 238
Study: 28186933

Group type: EXPERIMENTAL
Intervention: Diabetes Medication Choice Decision Aid
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 204
Study: 25143179

Group type: EXPERIMENTAL
Intervention: Dermatology consultation (treatment group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: PCP management (control group)
Number of subjects: 29
Study: 22422031

Group type: EXPERIMENTAL
Intervention: Surgery (25G vitrectomy and internal limiting membrane peeling with blue dye staining)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no surgery)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Surgery (in presence of VPA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (in presence of VPA)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Presence of intra-retinal cysts
Number of subjects: 76
Study: 19947131

Group type: EXPERIMENTAL
Intervention: Oraqix
Number of subjects: 45

Group type: COMPARATOR
Intervention: Benzocaine
Number of subjects: 45
Study: 17186295

Group type: EXPERIMENTAL
Intervention: Acipimox (LFA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both trials (LFA and CON)
Number of subjects: 9
Study: 15248230

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (combined etanercept and infliximab)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Etanercept (interrupted therapy)
Number of subjects: 15
Study: 12508476

Group type: EXPERIMENTAL
Intervention: Faropenem 300 mg 3 times daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levofloxacin 100 mg 3 times daily
Number of subjects: 60
Study: 8611664

Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 2680990

Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg b.i.d. for three days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. for three days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 1092515

Group type: EXPERIMENTAL
Intervention: Propranolol (1,600 mg, 240 mg, and 600 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31481062

Group type: EXPERIMENTAL
Intervention: Parent-group treatment focusing on evidence-based parenting practices
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard treatment focusing on lifestyle changes
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Baseline picky eating measured with the CEBQ
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Higher degree of picky eating at baseline (measured with the CEBQ)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: CEBQ and LBC measurements of picky eating
Number of subjects: 130
Study: 28436539

Group type: EXPERIMENTAL
Intervention: Selective screening using demographic characteristics
Number of subjects: 222

Group type: COMPARATOR
Intervention: Selective screening using behavioral indicators
Number of subjects: 222

Group type: COMPARATOR
Intervention: Random selective screening
Number of subjects: 222
Study: 25841133

Group type: EXPERIMENTAL
Intervention: 2500 IU heparin
Number of subjects: 459

Group type: COMPARATOR
Intervention: 5000 IU heparin
Number of subjects: 459
Study: 23521323

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study: 21807616

Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) for 10 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcranial static magnetic field stimulation (tSMS)
Number of subjects: 0
Study: 19468742

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at 20 HZ for 60 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study: 16643234

Group type: EXPERIMENTAL
Intervention: ILIH block at 1 cm inferio‐medial to the anterior superior iliac spine (ASIS) with 0.25 ml/kg of 0.25% bupivacaine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ILIH block at 1-2 cm medial to the ASIS with 0.25 ml/kg of 0.25% bupivacaine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ILIH block at 2 cm superio‐medial to the ASIS with 0.25 ml/kg of 0.25% bupivacaine
Number of subjects: 132

Group type: COMPARATOR
Intervention: No nerve block (control group)
Number of subjects: 132
Study: 14988445

Group type: EXPERIMENTAL
Intervention: High-quercetin onions
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-quercetin onions
Number of subjects: 8
Study: 11533266

Group type: EXPERIMENTAL
Intervention: Pecan-enriched diet (20% isoenergetic replacement with pecans)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Step I diet
Number of subjects: 23
Study: 9663365

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg plus Beano
Number of subjects: 37

Group type: COMPARATOR
Intervention: Acarbose 100 mg
Number of subjects: 37
Study: 7988249

Group type: EXPERIMENTAL
Intervention: Postoperative thoracic irradiation plus six cycles of CAP chemotherapy (cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Postoperative thoracic irradiation alone
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Postoperative thoracic irradiation plus six cycles of CAP chemotherapy
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Entire study population
Number of subjects: 172
Study: 3385548

Group type: EXPERIMENTAL
Intervention: Group III: meperidine, promethazine, and chlorpromazine intramuscular
Number of subjects: 58

Group type: COMPARATOR
Intervention: Group I: meperidine intramuscular
Number of subjects: 58

Group type: COMPARATOR
Intervention: Group II: atropine intramuscular and diazepam intravenous
Number of subjects: 58
Study: 30195894

Group type: EXPERIMENTAL
Intervention: Modified surface Goldmann applanation tonometer (GAT) prism
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard Goldmann applanation tonometer (GAT) prism
Number of subjects: 173
Study: 28031374

Group type: EXPERIMENTAL
Intervention: Intensive intervention package (interpersonal counseling on IYCF, mass media campaign, community mobilization)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Usual nutrition counseling and mass media campaign (nonintensive)
Number of subjects: 4000
Study: 26249206

Group type: EXPERIMENTAL
Intervention: Exenatide (EXE, n = 20)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Insulin (INS, n = 21)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO, n = 21)
Number of subjects: 62
Study: 23823849

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21445680

Group type: EXPERIMENTAL
Intervention: Intensive problem-based diabetes self-management training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Condensed problem-based diabetes self-management training
Number of subjects: 56
Study: 18664297

Group type: EXPERIMENTAL
Intervention: Borderline gestational diabetes mellitus (BGDM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants born to BGDM mothers
Number of subjects: 0
Study: 17249520

Group type: EXPERIMENTAL
Intervention: Temocapril
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control Hypertensives
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.3 mg)
Number of subjects: 70
Study: 12601517

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: tolterodine IR 2 mg twice daily
Number of subjects: 1235

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1235
Study: 11808059

Group type: EXPERIMENTAL
Intervention: Linseed extract
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Carboxymethyl cellulose preparation (Salinum and MAS‐84)
Number of subjects: 19
Study: 9316004

Group type: EXPERIMENTAL
Intervention: New combination chemotherapy regimen incorporating a new agent
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Mortality adjustment
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Slope analysis (SA) and area under the curve (AUC) analyses
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: More frequent evaluations of QL
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Following all patients until death
Number of subjects: 673
Study: 8175595

Group type: EXPERIMENTAL
Intervention: 0.3 g NaHCO3/kg body wt (alkalosis)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.04 g NaCl/kg body wt (control)
Number of subjects: 10
Study: 3308368

Group type: EXPERIMENTAL
Intervention: Milligan hemorrhoidectomy combined with anal dilatation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hemorrhoidectomy only
Number of subjects: 40
Study: 28883098

Group type: EXPERIMENTAL
Intervention: Weight-based estimation (insertion depth (cm) = weight (kg) +6)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Vocal cord guide
Number of subjects: 136
Study: 26628386

Group type: EXPERIMENTAL
Intervention: Original 15-item NIHSS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shortened versions of NIHSS (11, 8, and 5 items)
Number of subjects: 0
Study: 26580881

Group type: EXPERIMENTAL
Intervention: Hydrolyzed roe cream (Group 1, n=19)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 4% Glycolic acid (Group 2, n=17)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 8% Glycolic acid plus 2% citric acid (Group 3, n=16)
Number of subjects: 75
Study: 23601499

Group type: EXPERIMENTAL
Intervention: Terlipressin (group A, N = 23)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Noradrenaline (group B, N = 23)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Terlipressin (group A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Noradrenaline (group B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Noradrenaline
Number of subjects: 46
Study: 20625264

Group type: EXPERIMENTAL
Intervention: HIV-LIPO-5 50 microg/lipopeptide
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: HIV-LIPO-5 150 microg/lipopeptide
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: HIV-LIPO-5 500 microg/lipopeptide
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: HIV-LIPO-5 (all doses)
Number of subjects: 131
Study: 18664477

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg once daily
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Candesartan (high baseline fibrillatory rate >420 fpm)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Candesartan (intermediate baseline fibrillatory rate 360-420 fpm)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Candesartan (low baseline fibrillatory rate <360 fpm)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Candesartan (on-treatment rate <360 fpm)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Candesartan (on-treatment rate >360 fpm)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Candesartan effects on fibrillatory rate
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: AF recurrence risk
Number of subjects: 124
Study: 16325777

Group type: EXPERIMENTAL
Intervention: Lean individuals (BMI=23.2+/‐0.4 kg/m²)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Obese individuals (BMI=35.0+/‐1.1 kg/m²)
Number of subjects: 12
Study: 14570722

Group type: EXPERIMENTAL
Intervention: 30 micro g octreotide
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 100 micro g octreotide
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39